Perpetual Medicines Completes $8 Million Seed Round To Advance Integrated Computational Design-synthesis Platform For Peptide Drug Discovery

By Author: Otis
Total Articles: 386
Comment this article

Perpetual Medicines' comprehensive computational design and synthesis platform for peptide drug development advanced with a $8 million seed financing round lead by Chengwei Capital. The company uses recent advances in computer modeling, AI, deep learning, and machine learning to explore the large chemical space for peptide-based drug development.

Key Hires and Leadership:

Perpetual Medicines added Kerry L. Blanchard, MD, PhD, as Co-founder, Chairman, and CEO; Ved Srivastava, PhD, as Chief Technology Officer; and Xiang Ye, PhD, as Chief Scientific Officer. The team has 120 years of medicinal development experience, mostly in peptide therapies.

Drug Discovery by Computer:

Perpetual Medicines' computational platform offers virtual iteration via millions of peptide sequences. It uses physics-based simulations to predict binding and drug-like properties and experimental data integration to find and optimize therapeutic candidates. This novel approach could speed up peptide drug discovery, save expenses, and improve therapeutic prospects.

Growth and Market Potential:

The business wants to capitalize on the $140 billion peptide therapies market expected by 2030. Peptides, between small molecule medicines and therapeutic antibodies, block protein interactions inside and outside cells better. Perpetual Medicines hopes to discover new target classes and solve pathobiology with its extended chemical space.

Read More - https://bit.ly/3TbZtxn